Zecchetto, C.; Quinzii, A.; Casalino, S.; Gaule, M.; Pesoni, C.; Merz, V.; Pietrobono, S.; Mangiameli, D.; Pasquato, M.; Milleri, S.;
et al. Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab. J. Pers. Med. 2023, 13, 508.
https://doi.org/10.3390/jpm13030508
AMA Style
Zecchetto C, Quinzii A, Casalino S, Gaule M, Pesoni C, Merz V, Pietrobono S, Mangiameli D, Pasquato M, Milleri S,
et al. Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab. Journal of Personalized Medicine. 2023; 13(3):508.
https://doi.org/10.3390/jpm13030508
Chicago/Turabian Style
Zecchetto, Camilla, Alberto Quinzii, Simona Casalino, Marina Gaule, Camilla Pesoni, Valeria Merz, Silvia Pietrobono, Domenico Mangiameli, Martina Pasquato, Stefano Milleri,
and et al. 2023. "Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab" Journal of Personalized Medicine 13, no. 3: 508.
https://doi.org/10.3390/jpm13030508
APA Style
Zecchetto, C., Quinzii, A., Casalino, S., Gaule, M., Pesoni, C., Merz, V., Pietrobono, S., Mangiameli, D., Pasquato, M., Milleri, S., Giacopuzzi, S., Bencivenga, M., Tomezzoli, A., de Manzoni, G., & Melisi, D.
(2023). Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab. Journal of Personalized Medicine, 13(3), 508.
https://doi.org/10.3390/jpm13030508
